-+ 0.00%
-+ 0.00%
-+ 0.00%

Kangtai Biotech announced that the recombinant hepatitis B vaccine project developed by the company received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration today. According to the “Drug Administration Law of the People's Republic of China”, “Vaccine Administration Law of the People's Republic of China” and related regulations, after examination, this product met the relevant requirements for drug registration and approved to carry out clinical trials to prevent HBsAg recovery in people functionally cured of chronic hepatitis B.

Zhitongcaijing·12/17/2025 10:09:07
Listen to the news
Kangtai Biotech announced that the recombinant hepatitis B vaccine project developed by the company received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration today. According to the “Drug Administration Law of the People's Republic of China”, “Vaccine Administration Law of the People's Republic of China” and related regulations, after examination, this product met the relevant requirements for drug registration and approved to carry out clinical trials to prevent HBsAg recovery in people functionally cured of chronic hepatitis B.